BioXcel Therapeutics Ownership | Who Owns BioXcel Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

BioXcel Therapeutics Ownership Summary


BioXcel Therapeutics is owned by 7.32% institutional investors, 20.06% insiders, and 72.62% retail investors. Vanguard group is the largest institutional shareholder, holding 3.14% of BTAI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.18% of its assets in BioXcel Therapeutics shares.

BTAI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBioXcel Therapeutics7.32%20.06%72.62%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group970.43K3.14%$1.24M
Blackrock440.69K1.43%$564.08K
Bnp paribas arbitrage, snc273.13K0.88%$349.61K
Geode capital management266.72K0.86%$341.47K
Charles schwab investment management203.62K0.66%$260.63K
Northern trust194.95K0.63%$249.54K
Wells fargo & company/mn133.68K0.43%$171.10K
Jane street group125.05K0.41%$160.06K
State street124.75K0.40%$159.68K
Millennium management122.75K0.40%$157.12K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Point72 asia (singapore) pte.30.30K0.01%$38.78K
Virtu financial57.34K0.01%$73.00K
Xtx topco46.50K0.01%$59.52K
Arete wealth advisors43.50K0.00%$56.00K
Diversify wealth management40.00K0.00%$36.80K
Allsquare wealth management4.53K0.00%$5.79K
Hennion & walsh asset management40.60K0.00%$51.97K
Seacrest wealth management15.75K0.00%$20.16K
Tocqueville asset management43.75K0.00%$56.00K
Point72 (difc)15.40K0.00%$19.72K

Top Buyers

HolderShares% AssetsChange
Bnp paribas arbitrage, snc273.13K0.00%251.38K
Jane street group125.05K-125.05K
Millennium management122.75K0.00%77.63K
Goldman sachs group98.97K-76.20K
Citigroup55.77K-52.26K

Top Sellers

HolderShares% AssetsChange
Armistice capital---2.99M
Fmr---2.21M
Blackrock440.69K--887.38K
Ameriprise financial---579.16K
State street124.75K--340.16K

New Positions

HolderShares% AssetsChangeValue
Diversify wealth management40.00K0.00%40.00K$36.80K
Point72 asia (singapore) pte.30.30K0.01%30.30K$38.78K
Commonwealth equity services25.40K0.00%25.40K$33.00K
Lpl financial18.40K-18.40K$23.55K
Point72 (difc)15.40K0.00%15.40K$19.72K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-4.00
Farther finance advisors-82.00
New york state common retirement fund-273.00
Massmutual trust co fsb/adv-297.00
Russell investments group-344.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202450-33.33%3,102,869-68.25%70.73%12-72.73%2750.00%
Jun 30, 202475-2.60%9,773,3755.76%313.15%4451.72%18-28.00%
Mar 31, 202477-9,241,283-1.19%313.11%29-14.71%25-13.79%
Dec 31, 202377-14.44%9,352,370-8.29%312.62%34-15.00%29-9.38%
Sep 30, 202390-14.29%10,198,156-42.33%340.91%40-27.27%3239.13%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv886.25K2.18%-
Fidelity Growth Compy Commingled Pl O469.48K1.15%-425.27K
Fidelity Growth Company Fund353.64K0.87%-248.67K
Vanguard Institutional Extnd Mkt Idx Tr293.32K0.69%-
Fidelity Extended Market Index184.89K0.45%27.70K
Fidelity Growth Company K6163.94K0.40%-132.22K
Fidelity Series Growth Company88.26K0.22%-63.60K
iShares Micro-Cap ETF82.03K0.20%-
BSO Bio Santé C70.00K0.17%-
NT R2000 Growth Index Fund - NL57.60K0.14%-

Recent Insider Transactions


DateNameRoleActivityValue
Dec 16, 2024O'Neill Vincent See RemarksSell$58.13
Dec 16, 2024Mehta Vimal CEO and PresidentSell$773.36
Dec 16, 2024Mehta Vimal CEO and PresidentSell$357.91
Dec 16, 2024Steinhart Richard I Chief Financial OfficerSell$73.80
Dec 16, 2024Steinhart Richard I Chief Financial OfficerSell$133.18

Insider Transactions Trends


DateBuySell
2024 Q4-12
2024 Q3-7
2024 Q2-19
2024 Q1--
2023 Q4--

BTAI Ownership FAQ


Who Owns BioXcel Therapeutics?

BioXcel Therapeutics shareholders are primarily institutional investors at 7.32%, followed by 20.06% insiders and 72.62% retail investors. The average institutional ownership in BioXcel Therapeutics's industry, Biotech Stocks , is 47.04%, which BioXcel Therapeutics falls below.

Who owns the most shares of BioXcel Therapeutics?

BioXcel Therapeutics’s largest shareholders are Vanguard group (970.43K shares, 3.14%), Blackrock (440.68K shares, 1.43%), and Bnp paribas arbitrage, snc (273.14K shares, 0.88%). Together, they hold 5.46% of BioXcel Therapeutics’s total shares outstanding.

Does Blackrock own BioXcel Therapeutics?

Yes, BlackRock owns 1.43% of BioXcel Therapeutics, totaling 440.68K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 564.08K$. In the last quarter, BlackRock decreased its holdings by -887K shares, a -66.82% change.

Who is BioXcel Therapeutics’s biggest shareholder by percentage of total assets invested?

Point72 asia (singapore) pte is BioXcel Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.01% of its assets in 30.3K BioXcel Therapeutics shares, valued at 38.78K$.

Who is the top mutual fund holder of BioXcel Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of BioXcel Therapeutics shares, with 2.18% of its total shares outstanding invested in 886.24K BioXcel Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools